Journal of Clinical and Aesthetic Dermatology

MauiDerm Abstract Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/677940

Contents of this Issue

Navigation

Page 25 of 27

S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y [ M AY 2 0 1 6 • V O L U M E 9 • N U M B E R 5 ] BY ARTICLE TITLE A Randomized, Double-blind, Vehicle- controlled, Parallel Group Study of the Dose- response Profile of A-101 Solution in Subjects with Seborrheic Keratosis of the Face........S20 A Double-blind, Randomized Study to Compare Microcyn Scar Management HydroGel, K103163, and Kelo-cote Scar Gel for Hypertrophic or Keloid Scars .......................S8 Activity of Dapsone versus Community and Hospital Bacterial Pathogens from the Canward Study..............................................S4 Age and Gender as Predictors of Treatment Outcomes with Once-Daily Dapsone 7.5% Topical Gel for Acne Vulgaris........................S4 An In Vitro Study Demonstrating Nail Penetration of Tavaborole from Tavaborole Topical Solution, 5% through Multiple Layers of Nail Polish ..S11 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Moderate-to-severe Plaque Psoriasis: Pooled 16-Week Efficacy in Patient Subgroups (ESTEEM 1 and 2) .......S15 Apremilast for the Treatment of Psoriasis and Psoriatic Arthritis: Management of Gastrointestinal Adverse Effects.................S15 ATX-101 (Deoxycholic Acid Injection) is Safe and Effective in Men: Results from a Pooled Analysis of the REFINE Trials........................S5 Changes in Skin Laxity Among Responders to ATX-101 (Deoxycholic Acid Injection) in the REFINE Trials ..........................................S6 DFD-01, a Class 3/4 Betamethasone Dipropionate 0.05% Emollient Formulation Demonstrates Similar Efficacy to a Class 1 Topical Steroid for the Treatment of Moderate Psoriasis.....................................S13 DFD-01 A Novel Emollient Spray Formulation of 0.05% Betamethasone Dipropionate Effectively Treats Plaque Psoriasis on Knees and Elbows.......................................S14 Efficacy and Safety of Adalimumab versus Methotrexate Treatment in Pediatric Patients with Severe Chronic Plaque Psoriasis: Results from the 16-Week Randomized, Double-Blind Period of a Phase 3 Study ..........................S11 Efficacy and Safety of Dupilumab for Moderate- to-severe Atopic Dermatitis in Adults: A Pooled Analysis of Two Phase 2 Clinical Trials.........S9 Efficacy and Safety of Once-daily Dapsone Gel 7.5% for Treatment of Adolescents and Adults with Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Placebo-Controlled Trials..............................S3 Efficacy and Safety of Once-daily Dapsone Gel 7.5% for Treatment of Adolescents and Adults with Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Placebo-Controlled Trials..............................S3 Efficacy of CeraVe Itch Relief Lotion and Cream on Itch Relief in Patients with Atopic Dermatitis ........................................S10 Efficacy of Secukinumab in Patients with Plaque Psoriasis: Area Under the Curve of Treatment Response Rates..........................................S13 Evolution of Acne Assessments and Impact on Acne Medications: An Evolving, Imperfect Paradigm.......................................................S5 Long-term Use of Once-daily Brimonidine Gel 0.33% for Treating Facial Erythema of Rosacea, Improved Quality of Life, and Decreased Basal Levels of Erythema .....................................S20 Multicenter Pivotal Study of the Safety and Effectiveness of a Tissue Stabilized-Guided Subcision Procedure for the Treatment of Cellulite-Interim 3 Year Update.....................S8 Patient-reported Impact of Chronic Hives Relative to Psoriasis in the US ...................S21 Pregnancy Outcomes in the Tofacitinib Psoriasis Safety Database up to April 2014 ...............S19 Regression Analysis of Local Skin Responses to Predict Clearance of Actinic Keratoses on the Face in Patients Treated with Ingenol Mebutate Gel.................................................S9 Results From Two Phase 3 Studies in Children and Adults With Mild-to-moderate Atopic Dermatitis Treated with Crisaborole Topical Ointment, 2%, a Novel Nonsteroidal, Topical Anti-Inflammatory, Phosphodiesterase 4 Inhibitor.......................................................S10 Retrospective Safety Study of Combining Micro-Focused Ultrasound with Visualization (MFU-V) with Neurotoxins and Fillers (HA and CaHA) .....................................................S7 Safety and Efficacy of ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat: Results from a Multicenter, Open-Label Phase 3b Trial................................................S7 Safety of Apremilast and Etanercept Compared with Placebo in Patients with Moderate to Severe Psoriasis: Results From the LIBERATE Study .........................................S16 Secukinumab Administration by Prefilled Syringe Maintains Efficacy in Moderate-to-se- vere Plaque Psoriasis Over 100 Weeks: Results of the FEATURE Trial ...................................S18 Secukinumab Delivers Greater Improvement in Health-related Quality of Life Compared to Ustekinumab in Subjects With Moderate-to- severe Plaque Psoriasis: 16-Week Data From the CLEAR Study...............................S17 Secukinumab Exhibits Low Immunogenicity During 104 Weeks of Treatment in Subjects with Moderate-to-severe Plaque Psoriasis ........S17 Secukinumab in Psoriasis: Relationship Between Clinical- and Patient-reported Outcomes Using Clinical Trial Data from the ERASURE and FIXTURE Trials....................S14 Secukinumab is Predominantly Prescribed at the Recommended 300mg Dose to Psoriasis Patients in the United States.......................S18 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis ......S19 The Aerosol Foam Formulation Of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Is Efficacious In Patients with Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies .................S12 S 2 2 Alphabetical Index of Posters

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - MauiDerm Abstract Supplement 2016